Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 5/20 | 0.61 |
| ▸ | MAPK3 | P27361 | 5/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.54 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 7/20 | 0.52 |
| ▸ | ROS1 | P08922 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10083888 | 0.92 | ALK (0.55) | ALKMAPK3METGLO1EGFR | |
| SCHEMBL604081 | 0.92 | ALK (0.55) | ALKMAPK3METGLO1EGFR | |
| SCHEMBL603382 | 0.90 | MAPK3 (0.52) | ALKMAPK3METGLO1EGFR | |
| SCHEMBL10083854 | 0.90 | ALK (0.53) | ALKMAPK3METGLO1EGFR | |
| SCHEMBL626247 | 0.90 | GLO1 (0.56) | ALKMAPK3METGLO1EGFR | |
| SCHEMBL13084448 | 0.88 | GLO1 (0.58) | ALKMAPK3METGLO1EGFR | |
| SCHEMBL10074537 | 0.88 | MAPK3 (0.58) | ALKMAPK3METGLO1EGFR | |
| SCHEMBL600331 | 0.87 | GLO1 (0.54) | ALKMAPK3METGLO1EGFR | |
| SCHEMBL602400 | 0.87 | ALK (0.58) | ALKMAPK3METGLO1EGFR | |
| SCHEMBL10084072 | 0.86 | PTK2 (0.63) | ALKMETGLO1EGFRPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040955-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-16 | — | — | US | claimed |
| EP-2419423-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | Cellzome Limited (GB) | 2012-02-22 | — | — | EP | disclosed |
| US-20120040955-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040955-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| WO-2010118986-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010118986-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040955-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | ALK 1095/4885MAPK3 19/4885MET 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.